RxDoctor Payments Data

Amanda Wright

Family · Wytheville, VANPI 1306367149

Payments from drug & device makers

$1,308in general payments, 2019–2025

Across 75 payments — averaging $17.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$261
  • AbbVie$184
  • Xeris Pharmaceuticals, Inc.$134
  • Novo Nordisk$107
  • Johnson & Johnson$88
  • Lilly USA, LLC$78
  • plus $455 from 16 others

What the payments were for

  • Food & beverage$1,308100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,308 in reported general payments places this provider in the 75th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$33,845
Medicare patients
117
Services billed
524

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide97$164,464
EliquisApixaban48$53,758
TrulicityDulaglutide30$48,773
FarxigaDapagliflozin Propanediol39$48,397
Breztri AerosphereBudesonide/Glycopyr/Formoterol39$29,565
Spiriva RespimatTiotropium Bromide25$27,656
JanuviaSitagliptin Phosphate20$26,740
VraylarCariprazine Hcl13$20,055
XareltoRivaroxaban16$13,424
ZenpepLipase/Protease/Amylase13$6,929
JanumetSitagliptin Phos/Metformin Hcl11$6,168
SymbicortBudesonide/Formoterol Fumarate12$5,814
Lantus SolostarInsulin Glargine,hum.Rec.Anlog36$5,472
Dexlansoprazole DrDexlansoprazole22$4,151
Pregabalin69$3,485

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$107$164,46497 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$261$83,77690 claims
PfizerEliquis$27$53,75848 claims
Lilly USA, LLCTrulicity$78$48,77330 claims
Boehringer IngelheimSpiriva Respimat$13$27,65625 claims
AbbVieVraylar$184$20,05513 claims
Johnson & JohnsonXarelto$88$13,42416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,332 family providers in Virginia.

Other family in Wytheville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →